Altered peripheral immune profiles in treatment-resistant depression: Response to ketamine and prediction of treatment outcome

Translational Psychiatry

Volumn 7, Issue 3, 2017, Pages

  Kiraly, D D ^a   Horn, S R ^a   Van Dam, N T ^a   Costi, S ^a   Schwartz, J ^a   Kim Schulze, S ^a   Patel, M ^a   Hodes, G E ^a   Russo, S J ^a   Merad, M ^a   Iosifescu, D V ^a   Charney, D S ^a   Murrough, J W ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COLONY STIMULATING FACTOR; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; KETAMINE; TUMOR NECROSIS FACTOR; AMINO ACID RECEPTOR BLOCKING AGENT; CYTOKINE; IL1A PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; SIGNAL PEPTIDE; TNF PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATION; MALE; PSYCHOPHARMACOTHERAPY; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; CASE CONTROL STUDY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR DEPRESSION; MIDDLE AGED; PROGNOSIS;

ADULT; CASE-CONTROL STUDIES; CHEMOKINES; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFLAMMATION; INFUSIONS, INTRAVENOUS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; KETAMINE; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85029295421     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2017.31     Document Type: Article

References (52)

1. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry 2006; 163: 1905-1917.
3. Hodes GE, Kana V, Menard C, Merad M, Russo SJ. Neuroimmune mechanisms of depression. Nat Neurosci 2015; 18: 1386-1393.
4. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-741.
5. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A metaanalysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
6. Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: depression fans the flames and feasts on the heat. Am J Psychiatry 2015; 172: 1075-1091.
7. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014; 71: 1121-1128.
8. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853-858.
9. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-379.
10. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31-41.
11. Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71: 1381-1391.
12. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012; 62: 63-77.
13. Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 2012; 13: 22-37.
14. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.
15. Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014; 76: 970-976.
16. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134-1142.
17. De Kock M, Loix S, Lavand'homme P. Ketamine and peripheral inflammation. CNS Neurosci Ther 2013; 19: 403-410.
18. Dale O, Somogyi AA, Li Y, Sullivan T, Shavit Y. Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. Anesth Analg 2012; 115: 934-943.
19. Yang C, Hong T, Shen J, Ding J, Dai XW, Zhou ZQ et al. Ketamine exerts antidepressant effects and reduces IL-1β and IL-6 levels in rat prefrontal cortex and hippocampus. Exp Ther Med 2013; 5: 1093-1096.
20. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013; 38: 1609-1616.
21. Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 2015; 77: e19-e20.
22. Park M, Newman LE, Gold PW, Luckenbaugh DA, Yuan P, Machado-Vieira R et al. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. J Psychiatr Res 2016; 84: 113-118.
23. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2015; 16: 22-34.
24. Miller AH. Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression. Neuropsychopharmacology 2013; 38: 1607-1608.
25. Haroon E, Woolwine BJ, Chen X, Pace TW, Parekh S, Spivey JR et al. IFN-alphainduced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 2014; 39: 1777-1785.
26. Haroon E, Fleischer CC, Felger JC, Chen X, Woolwine BJ, Patel T et al. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry 2016; 21: 1351-1357.
27. Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry 2015; 21: 1358-1365.
28. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007; 41: 326-331.
29. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010; 25: 201-215.
30. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 2015; 49: 206-215.
31. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSMIV Axis I Disorders, Patient Edition (SCID-P), version 2. New York State Psychiatric Institute, Biometrics Research: New York, NY, 1995.
32. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001; 62: 10-17.
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
34. Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology 2015; 40: 1084-1090.
35. Hodes GE, Pfau ML, Leboeuf M, Golden SA, Christoffel DJ, Bregman D et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci USA 2014; 111: 16136-16141.
36. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-544.
37. D'Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci 2009; 29: 2089-2102.
38. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun 2014; 42: 50-59.
39. Wohleb ES, Powell ND, Godbout JP, Sheridan JF. Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. J Neurosci 2013; 33: 13820-13833.
40. Wohleb ES, Patterson JM, Sharma V, Quan N, Godbout JP, Sheridan JF. Knockdown of interleukin-1 receptor type-1 on endothelial cells attenuated stressinduced neuroinflammation and prevented anxiety-like behavior. J Neurosci 2014; 34: 2583-2591.
41. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB et al. Ketamine and other nmda antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172: 950-966.
42. Duncan WC, Selter J, Brutsche N, Sarasso S, Zarate CA. Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. J Affect Disord 2013; 145: 115-119.
43. Salvadore G, van der Veen JW, Zhang Y, Marenco S, Machado-Vieira R, Baumann J et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol 2012; 15: 1063-1072.
44. Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 2014; 75: e417-e423.
45. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry 2014; 75: e932-e938.
46. Ortiz R, Niciu MJ, Lukkahati N, Saligan LN, Nugent AC, Luckenbaugh DA et al. Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. J Affect Disord 2014; 172C: 307-311.
47. Machado-Vieira R, Gold PW, Luckenbaugh DA, Ballard ED, Richards EM, Henter ID et al. The role of adipokines in the rapid antidepressant effects of ketamine. Mol Psychiatry 2016; 22: 127-133.
48. He S, Zhang T, Hong B, Peng D, Su H, Lin Z et al. Decreased serum fibroblast growth factor-2 levels in pre-and post-treatment patients with major depressive disorder. Neurosci Lett 2014; 579: 168-172.
49. Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H et al. Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 2004; 101: 15506-15511.
50. Elsayed M, Banasr M, Duric V, Fournier NM, Licznerski P, Duman RS. Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry 2012; 72: 258-265.
51. Birey F, Kloc M, Chavali M, Hussein I, Wilson M, Christoffel DJ et al. Genetic and stress-induced loss of NG2 glia triggers emergence of depressive-like behaviors through reduced secretion of FGF2. Neuron 2015; 88: 941-956.
52. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.